Bristol Myers' Zeposia expansion plans hit by Phase 3 setback in Crohn's disease
One of Bristol Myers Squibb’s top new immunology products has failed a Phase 3 study, denting hopes of growing the franchise through a new indication …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
